Jump to content

Secondary hypertension

From Wikipedia, the free encyclopedia

Secondary hypertension
Other namesInessential hypertension
SpecialtyCardiology, nephrology Edit this on Wikidata

Secondary hypertension (or, less commonly, inessential hypertension) is a type of hypertension which has a specific and identifiable underlying primary cause. It is much less common than essential hypertension, affecting only 5-10% of hypertensive patients. It has many different causes including obstructive sleep apnea, kidney disease, endocrine diseases, and tumors. The cause of secondary hypertension varies significantly with age.[1] It also can be a side effect of many medications.

Common causes

[edit]

Obstructive sleep apnea

[edit]
Main article: Obstructive sleep apnea

Obstructive sleep apnea (OSA) is one of the most common causes of secondary hypertension.[2] OSA is prevalent in older adults and should be considered in cases of resistant hypertension, hypertension refractory to appropriate aggressive medical therapy.[3] OSA remains an under-diagnosed cause of secondary hypertension, likely due to the fact that many of the risk factors associated with OSA such as obesity, advanced age, and cigarette smoking are shared with primary hypertension. The intermittent hypoxia and resultant hypercapnia that is characteristic of OSA leads to activation of the sympathetic nervous system and leads to elevated blood pressure.[4][5] As with all cases of secondary hypertension, the goal of treating patients with hypertension due to OSA is addressing the underlying cause.[6] Therefore, weight loss and noctural nasal continuous positive airway pressure (CPAP) are mainstays in treating hypertension secondary to OSA. Other approaches include the mandibular advancement splint (MAS), UPPP, tonsillectomy, adenoidectomy, or septoplasty.[7]

Kidney disorders

[edit]

Renovascular disorders

[edit]
Main article: Renovascular hypertension

Obstruction of the renal arteries supplying the kidney that result in elevated blood pressure is known as renovascular hypertension. It is thought that decreased perfusion of renal tissue due to stenosis of a main or branch renal artery activates the renin–angiotensin system.[8][9][10] There are two main causes of renovascular hypertension: renal artery stenosis and fibromuscular dysplasia.[citation needed]

The normal physiological response to low blood pressure in the renal arteries is to increase cardiac output (CO) to maintain the pressure needed for glomerular filtration. Here, however, increased CO cannot solve the structural problems causing renal artery hypotension, with the result that CO remains chronically elevated.[citation needed]

Renal parenchymal disease

[edit]

This includes diseases such as polycystic kidney disease which is a cystic genetic disorder of the kidneys, PKD, which is characterized by the presence of multiple cysts (hence, "polycystic") in both kidneys, can also damage the liver, pancreas, and rarely, the heart and brain.[11][12][13][14] It can be autosomal dominant or autosomal recessive, with the autosomal dominant form being more common and characterized by progressive cyst development and bilaterally enlarged kidneys with multiple cysts, with concurrent development of hypertension, chronic kidney disease and kidney pain.[15] Or chronic glomerulonephritis which is a disease characterized by inflammation of the glomeruli, or small blood vessels in the kidneys.[16][17][18]

Chronic kidney disease

[edit]

Hypertension is common in chronic kidney disease.[citation needed]

Endocrine disorders

[edit]

Medication side effects

[edit]

Certain medications, including NSAIDs (ibuprofen/Motrin) and steroids can cause hypertension.[19][20][21][22][23] Other medications include estrogens (such as those found in oral contraceptives with high estrogenic activity), certain antidepressants (such as venlafaxine), buspirone, carbamazepine, bromocriptine, clozapine, and cyclosporine.[24] High blood pressure that is associated with the sudden withdrawal of various antihypertensive medications is called rebound hypertension.[25][26][27][28][29][30][31] The increases in blood pressure may result in blood pressures greater than when the medication was initiated. Depending on the severity of the increase in blood pressure, rebound hypertension may result in a hypertensive emergency. Rebound hypertension is avoided by gradually reducing the dose (also known as "dose tapering"), thereby giving the body enough time to adjust to reduction in dose. Medications commonly associated with rebound hypertension include centrally-acting antihypertensive agents, such as clonidine[32] and methyl-dopa.[31]

Other herbal or "natural products" which have been associated with hypertension include Ephedra, St John's wort, and licorice.[24]

Pregnancy

[edit]

Few women of childbearing age have high blood pressure, up to 11% develop hypertension of pregnancy.[33] While generally benign, it may herald three complications of pregnancy: pre-eclampsia, HELLP syndrome and eclampsia. Follow-up and control with medication is therefore often necessary.[34][35]

Uncommon causes

[edit]

Other kidney disorders

[edit]

Some renal tumors can cause hypertension. The differential diagnosis of a renal tumor in a young patient with hypertension includes juxtaglomerular cell tumor, Wilms' tumor, and renal cell carcinoma, all of which may produce renin.[36]

Other endocrine disorders

[edit]

Adrenal

[edit]

A variety of adrenal cortical abnormalities can cause hypertension, In primary aldosteronism there is a clear relationship between the aldosterone-induced sodium retention and the hypertension.[38]

Congenital adrenal hyperplasia, a group of autosomal recessive disorders of the enzymes responsible for steroid hormone production, can lead to secondary hypertension by creating atypically high levels of mineralocorticoid steroid hormones. These mineralocorticoids cross-react with the aldosterone receptor, activating it and raising blood pressure.[citation needed]

Yet another related disorder causing hypertension is glucocorticoid remediable aldosteronism, which is an autosomal dominant disorder in which the increase in aldosterone secretion produced by ACTH is no longer transient, causing of primary hyperaldosteronism, the Gene mutated will result in an aldosterone synthase that is ACTH-sensitive, which is normally not.[46][47][48][49][50] GRA appears to be the most common monogenic form of human hypertension.[51]

Compare these effects to those seen in Conn's disease, an adrenocortical tumor which causes excess release of aldosterone,[52] that leads to hypertension.[53][54][55]

Another adrenal related cause is Cushing's syndrome which is a disorder caused by high levels of cortisol. Cortisol is a hormone secreted by the cortex of the adrenal glands. Cushing's syndrome can be caused by taking glucocorticoid drugs, or by tumors that produce cortisol or adrenocorticotropic hormone (ACTH).[56] More than 80% of patients with Cushing's syndrome develop hypertension.,[57] which is accompanied by distinct symptoms of the syndrome, such as central obesity, lipodystrophy, moon face, sweating, hirsutism and anxiety.[58]

Neuroendocrine tumors are also a well known cause of secondary hypertension. Pheochromocytoma[59] (most often located in the adrenal medulla) increases secretion of catecholamines such as epinephrine and norepinephrine, causing excessive stimulation of adrenergic receptors, which results in peripheral vasoconstriction and cardiac stimulation. This diagnosis is confirmed by demonstrating increased urinary excretion of epinephrine and norepinephrine and/or their metabolites (vanillylmandelic acid).[citation needed]

Other sleep disturbances

[edit]

Another cause is an exceptionally rare neurological disease called Binswanger's disease, causing dementia; it is a rare form of multi-infarct dementia, and is one of the neurological syndromes associated with hypertension.[60]

Arsenic exposure

[edit]

Because of the ubiquity of arsenic in ground water supplies and its effect on cardiovascular health, low dose arsenic poisoning should be inferred as a part of the pathogenesis of idiopathic hypertension. Idiopathic and essential are both somewhat synonymous with primary hypertension. Arsenic exposure has also many of the same signs of primary hypertension such as headache, somnolence,[61] confusion, proteinuria,[62] visual disturbances, and nausea and vomiting.[63]

Potassium deficiency

[edit]

Due to the role of intracellular potassium in regulation of cellular pressures related to sodium, establishing potassium balance has been shown to reverse hypertension. [64]

Other causes of secondary hypertension

[edit]

Diagnosis

[edit]

The ABCDE mnemonic can be used to help determine a secondary cause of hypertension.

  • A: Accuracy, Apnea, Aldosteronism
  • B: Bruits, Bad Kidney
  • C: Catecholamines, Coarctation of the Aorta, Cushing's Syndrome
  • D: Drugs, Diet
  • E: Erythropoietin, Endocrine Disorders[69]

See also

[edit]

References

[edit]
  1. ^ Viera, Anthony J.; Neutze, Dana M. (15 December 2010). "Diagnosis of secondary hypertension: an age-based approach". American Family Physician. 82 (12): 1471–1478. ISSN 1532-0650. PMID 21166367.
  2. ^ Pedrosa, Rodrigo P.; Drager, Luciano F.; Gonzaga, Carolina C.; Sousa, Marcio G.; de Paula, Lílian K.G.; Amaro, Aline C.S.; Amodeo, Celso; Bortolotto, Luiz A.; Krieger, Eduardo M.; Bradley, T. Douglas; Lorenzi-Filho, Geraldo (November 2011). "Obstructive Sleep Apnea: The Most Common Secondary Cause of Hypertension Associated With Resistant Hypertension". Hypertension. 58 (5): 811–817. doi:10.1161/HYPERTENSIONAHA.111.179788. ISSN 0194-911X. PMID 21968750.
  3. ^ Senaratna, Chamara V.; Perret, Jennifer L.; Lodge, Caroline J.; Lowe, Adrian J.; Campbell, Brittany E.; Matheson, Melanie C.; Hamilton, Garun S.; Dharmage, Shyamali C. (August 2017). "Prevalence of obstructive sleep apnea in the general population: A systematic review". Sleep Medicine Reviews. 34: 70–81. doi:10.1016/j.smrv.2016.07.002. ISSN 1532-2955. PMID 27568340.
  4. ^ Eskandari, Davoud; Zou, Ding; Grote, Ludger; Schneider, Hartmut; Penzel, Thomas; Hedner, Jan (28 June 2017). "Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea". Respiratory Research. 18 (1): 130. doi:10.1186/s12931-017-0607-9. ISSN 1465-993X. PMC 5490198. PMID 28659192.
  5. ^ Pack AI, Gislason T (2009). "Obstructive sleep apnea and cardiovascular disease: a perspective and future directions". Progress in Cardiovascular Diseases. 51 (5): 434–51. doi:10.1016/j.pcad.2009.01.002. PMID 19249449.
  6. ^ Drager, Luciano F.; Togeiro, Sônia M.; Polotsky, Vsevolod Y.; Lorenzi-Filho, Geraldo (13 August 2013). "Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome". Journal of the American College of Cardiology. 62 (7): 569–576. doi:10.1016/j.jacc.2013.05.045. ISSN 1558-3597. PMC 4461232. PMID 23770180.
  7. ^ Silverberg DS, Iaina A, Oksenberg A (January 2002). "Treating Obstructive Sleep Apnea Improves Essential Hypertension and Quality of Life". American Family Physician. 65 (2): 229–36. PMID 11820487.
  8. ^ Textor SC (May 2009). "Current Approaches to Renovascular Hypertension". The Medical Clinics of North America. 93 (3): 717–32, Table of Contents. doi:10.1016/j.mcna.2009.02.012. PMC 2752469. PMID 19427501. Retrieved 19 June 2009.
  9. ^ Voiculescu A, Rump LC (January 2009). "[Hypertension in patients with renal artery stenosis]". Der Internist (in German). 50 (1): 42–50. doi:10.1007/s00108-008-2198-5. PMID 19096816.
  10. ^ Kendrick J, Chonchol M (October 2008). "Renal artery stenosis and chronic ischemic nephropathy: epidemiology and diagnosis". Advances in Chronic Kidney Disease. 15 (4): 355–62. doi:10.1053/j.ackd.2008.07.004. PMID 18805381.
  11. ^ Ecder T, Schrier RW (April 2009). "Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease". Nature Reviews Nephrology. 5 (4): 221–28. doi:10.1038/nrneph.2009.13. PMC 2720315. PMID 19322187.
  12. ^ Gross P (May 2008). "Polycystic kidney disease: will it become treatable?". Polskie Archiwum Medycyny Wewnȩtrznej. 118 (5): 298–301. PMID 18619180. Retrieved 19 June 2009.
  13. ^ Masoumi A, Reed-Gitomer B, Kelleher C, Schrier RW (2007). "Potential pharmacological interventions in polycystic kidney disease". Drugs. 67 (17): 2495–510. doi:10.2165/00003495-200767170-00004. PMID 18034588. S2CID 7041761.
  14. ^ Chapman AB (May 2007). "Autosomal dominant polycystic kidney disease: time for a change?". Journal of the American Society of Nephrology. 18 (5): 1399–407. doi:10.1681/ASN.2007020155. PMID 17429048. Retrieved 19 June 2009.
  15. ^ Chapman AB (July 2008). "Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies". Clinical Journal of the American Society of Nephrology. 3 (4): 1197–204. doi:10.2215/CJN.00060108. PMID 18579674. Retrieved 19 June 2009.
  16. ^ Berthoux FC, Mohey H, Afiani A (January 2008). "Natural history of primary IgA nephropathy". Seminars in Nephrology. 28 (1): 4–9. doi:10.1016/j.semnephrol.2007.10.001. PMID 18222341. Retrieved 19 June 2009.
  17. ^ D'Cruz D (February 2009). "Renal manifestations of the antiphospholipid syndrome". Current Rheumatology Reports. 11 (1): 52–60. doi:10.1007/s11926-009-0008-2. PMID 19171112. S2CID 23082656.
  18. ^ Licht C, Fremeaux-Bacchi V (February 2009). "Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis". Thrombosis and Haemostasis. 101 (2): 271–78. doi:10.1160/th08-09-0575. PMID 19190809. S2CID 1436800. Retrieved 19 June 2009.
  19. ^ Simone Rossi, ed. (2006). Australian medicines handbook 2006. Adelaide: Australian Medicines Handbook Pty Ltd. ISBN 978-0-9757919-2-9.[page needed]
  20. ^ White WB (May 2009). "Defining the problem of treating the patient with hypertension and arthritis pain". The American Journal of Medicine. 122 (5 Suppl): S3–9. doi:10.1016/j.amjmed.2009.03.002. PMID 19393824.
  21. ^ Mackenzie IS, Rutherford D, MacDonald TM (2008). "Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis". Arthritis Research & Therapy. 10 (Suppl 2): S3. doi:10.1186/ar2464. PMC 2582806. PMID 19007428.
  22. ^ Berenbaum F (2008). "New horizons and perspectives in the treatment of osteoarthritis". Arthritis Research & Therapy. 10 (Suppl 2): S1. doi:10.1186/ar2462. PMC 2582808. PMID 19007426.
  23. ^ Akinbamowo AO, Salzberg DJ, Weir MR (October 2008). "Renal consequences of prostaglandin inhibition in heart failure". Heart Failure Clinics. 4 (4): 505–10. doi:10.1016/j.hfc.2008.03.002. PMID 18760760.
  24. ^ a b c Chobanian AV, et al. (2003). "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report". JAMA. 289 (19): 2560–72. doi:10.1001/jama.289.19.2560. PMID 12748199.
  25. ^ Lowenstein J (January 1980). "Drugs five years later: clonidine". Annals of Internal Medicine. 92 (1): 74–77. doi:10.7326/0003-4819-92-1-74. PMID 6101302.
  26. ^ Robertson JI (January 1997). "Risk factors and drugs in the treatment of hypertension". Journal of Hypertension Supplement. 15 (1): S43–6. doi:10.1097/00004872-199715011-00006. PMID 9050985. S2CID 28804593.
  27. ^ Schachter M (August 1999). "Moxonidine: a review of safety and tolerability after seven years of clinical experience". Journal of Hypertension Supplement. 17 (3): S37–9. PMID 10489097.
  28. ^ Schäfer SG, Kaan EC, Christen MO, Löw-Kröger A, Mest HJ, Molderings GJ (July 1995). "Why imidazoline receptor modulator in the treatment of hypertension?". Annals of the New York Academy of Sciences. 763 (1): 659–72. Bibcode:1995NYASA.763..659S. doi:10.1111/j.1749-6632.1995.tb32460.x. PMID 7677385. S2CID 9634310.
  29. ^ Larsen R, Kleinschmidt S (April 1995). "[Controlled hypotension]". Der Anaesthesist (in German). 44 (4): 291–308. doi:10.1007/s001010050157. PMID 7785759. S2CID 46283051.
  30. ^ Scholtysik G (March 1986). "Animal pharmacology of guanfacine". The American Journal of Cardiology. 57 (9): 13E–17E. doi:10.1016/0002-9149(86)90717-4. PMID 3006469.
  31. ^ a b Myers MG (January 1977). "New drugs in hypertension". Canadian Medical Association Journal. 116 (2): 173–76. PMC 1879000. PMID 343894.
  32. ^ van Zwieten PA, Thoolen MJ, Timmermans PB (1984). "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine". Hypertension. 6 (5 Pt 2): II28–33. doi:10.1161/01.hyp.6.5_pt_2.ii28. PMID 6094346.
  33. ^ Kang A, Struben H (November 2008). "[Pre-eclampsia screening in first and second trimester]". Therapeutische Umschau (in German). 65 (11): 663–66. doi:10.1024/0040-5930.65.11.663. PMID 18979429.
  34. ^ Marik PE (March 2009). "Hypertensive disorders of pregnancy". Postgraduate Medicine. 121 (2): 69–76. doi:10.3810/pgm.2009.03.1978. PMID 19332964. S2CID 207564356. Retrieved 18 June 2009.
  35. ^ Mounier-Vehier C, Delsart P (April 2009). "[Pregnancy-related hypertension: a cardiovascular risk situation]". Presse Médicale (in French). 38 (4): 600–08. doi:10.1016/j.lpm.2008.11.018. PMID 19250798. Retrieved 18 June 2009.
  36. ^ Méndez GP, Klock C, Nosé V (December 2008). "Juxtaglomerular Cell Tumor of the Kidney: Case Report and Differential Diagnosis With Emphasis on Pathologic and Cytopathologic Features". Int. J. Surg. Pathol. 19 (1): 93–98. doi:10.1177/1066896908329413. PMID 19098017. S2CID 38702564.
  37. ^ Samuel J Mann (2003). "Neurogenic essential hypertension revisited: the case for increased clinical and research attention". American Journal of Hypertension. 16 (10): 881–88. doi:10.1016/S0895-7061(03)00978-6. PMID 14553971.
  38. ^ Giacchetti G, Turchi F, Boscaro M, Ronconi V (April 2009). "Management of primary aldosteronism: its complications and their outcomes after treatment". Current Vascular Pharmacology. 7 (2): 244–49. doi:10.2174/157016109787455716. PMID 19356005.
  39. ^ "C-17 Hydroxylase Deficiency: Practice Essentials, Pathophysiology, Epidemiology". Medscape. February 2018.
  40. ^ Bailey MA, Paterson JM, Hadoke PW, et al. (January 2008). "A Switch in the Mechanism of Hypertension in the Syndrome of Apparent Mineralocorticoid Excess". Journal of the American Society of Nephrology. 19 (1): 47–58. doi:10.1681/ASN.2007040401. PMC 2391031. PMID 18032795.
  41. ^ Vantyghem MC, Marcelli-Tourvieille S, Defrance F, Wemeau JL (October 2007). "11beta-hydroxysteroide dehydrogenases. Recent advances". Annales d'endocrinologie (in French). 68 (5): 349–56. doi:10.1016/j.ando.2007.02.003. PMID 17368420.
  42. ^ Atanasov AG, Ignatova ID, Nashev LG, et al. (April 2007). "Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess". Journal of the American Society of Nephrology. 18 (4): 1262–70. doi:10.1681/ASN.2006111235. PMID 17314322. Retrieved 19 June 2009.
  43. ^ a b Johns C (January 2009). "Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars". Canadian Journal of Emergency Medical Care. 11 (1): 94–96. doi:10.1017/s1481803500010988. PMID 19166646.
  44. ^ Sontia B, Mooney J, Gaudet L, Touyz RM (February 2008). "Pseudohyperaldosteronism, liquorice, and hypertension". Journal of Clinical Hypertension. 10 (2): 153–57. doi:10.1111/j.1751-7176.2008.07470.x. PMC 8109973. PMID 18256580. S2CID 20098685.
  45. ^ Whitworth, Judith (December 2015). "Cardiovascular Consequences of Cortisol Excess". Vasc Health Risk Manag. 1 (4): 291–99. doi:10.2147/vhrm.2005.1.4.291. PMC 1993964. PMID 17315601.
  46. ^ Escher G (April 2009). "Hyperaldosteronism in pregnancy". Therapeutic Advances in Cardiovascular Disease. 3 (2): 123–32. doi:10.1177/1753944708100180. PMID 19171690.
  47. ^ Sukor N, Mulatero P, Gordon RD, et al. (August 2008). "Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families". Journal of Hypertension. 26 (8): 1577–82. doi:10.1097/HJH.0b013e3283028352. PMID 18622235. S2CID 46607812.
  48. ^ Omura M, Nishikawa T (May 2006). "[Glucocorticoid remediable aldosteronism]". Nippon Rinsho (in Japanese). Suppl 1: 628–34. PMID 16776234.
  49. ^ Luft FC (October 2003). "Mendelian Forms of Human Hypertension and Mechanisms of Disease". Clinical Medicine & Research. 1 (4): 291–300. doi:10.3121/cmr.1.4.291. PMC 1069058. PMID 15931322.
  50. ^ Nicod J, Dick B, Frey FJ, Ferrari P (February 2004). "Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production". Molecular and Cellular Endocrinology. 214 (1–2): 167–74. doi:10.1016/j.mce.2003.10.056. PMID 15062555. S2CID 617448.
  51. ^ McMahon GT, Dluhy RG (2004). "Glucocorticoid-remediable aldosteronism". Cardiology in Review. 12 (1): 44–48. doi:10.1097/01.crd.0000096417.42861.ce. PMID 14667264. S2CID 2813697.
  52. ^ Ziaja J, Cholewa K, Mazurek U, Cierpka L (2008). "[Molecular basics of aldosterone and cortisol synthesis in normal adrenals and adrenocortical adenomas]". Endokrynologia Polska (in Polish). 59 (4): 330–39. PMID 18777504.
  53. ^ Astegiano M, Bresso F, Demarchi B, et al. (March 2005). "Association between Crohn's disease and Conn's syndrome. A report of two cases". Panminerva Medica. 47 (1): 61–4. PMID 15985978.
  54. ^ Pereira RM, Michalkiewicz E, Sandrini F, et al. (October 2004). "[Childhood adrenocortical tumors]". Arquivos Brasileiros de Endocrinologia e Metabologia (in Portuguese). 48 (5): 651–58. doi:10.1590/S0004-27302004000500010. PMID 15761535.
  55. ^ Kievit J, Haak HR (March 2000). "Diagnosis and treatment of adrenal incidentaloma. A cost-effectiveness analysis". Endocrinology and Metabolism Clinics of North America. 29 (1): 69–90, viii–ix. doi:10.1016/S0889-8529(05)70117-1. PMID 10732265.
  56. ^ Kumar, Abbas, Fausto. Robbins and Cotran Pathologic Basis of Disease, 7th ed. Elsevier-Saunders; New York, 2005.
  57. ^ Dodt C, Wellhöner JP, Schütt M, Sayk F (January 2009). "[Glucocorticoids and hypertension]". Der Internist (in German). 50 (1): 36–41. doi:10.1007/s00108-008-2197-6. PMID 19096817. S2CID 35266216.
  58. ^ Yudofsky, Stuart C.; Robert E. Hales (2007). The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences (5th ed.). American Psychiatric Pub, Inc. ISBN 978-1-58562-239-9.
  59. ^ Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM (December 2008). "Catecholamine-induced cardiomyopathy". Endocrine Practice. 14 (9): 1137–49. doi:10.4158/ep.14.9.1137. PMID 19158054. Retrieved 19 June 2009.
  60. ^ Tomimoto H, Ihara M, Takahashi R, Fukuyama H (November 2008). "[Functional imaging in Binswanger's disease]". Rinsho Shinkeigaku (in Japanese). 48 (11): 947–50. doi:10.5692/clinicalneurol.48.947. PMID 19198127.
  61. ^ Arsenic trioxide drugs dot com
  62. ^ atsdr-medical management guidelines for arsenic trioxide
  63. ^ Arsenic Author: Frances M Dyro, MD, Chief of the Neuromuscular Section, Associate Professor, Department of Neurology, New York Medical College, Westchester Medical Center
  64. ^ Addison WL (March 1928). "The Use of Sodium Chloride, Potassium Chloride, Sodium Bromide, and Potassium Bromide in Cases of Arterial Hypertension which are Amenable to Potassium Chloride". Can Med Assoc J. 18 (3): 281–85. PMC 1710082. PMID 20316740.
  65. ^ a b Rivasi, G; Menale, S; Turrin, G; Coscarelli, A; Giordano, A; Ungar, A (October 2022). "The Effects of Pain and Analgesic Medications on Blood Pressure". Current Hypertension Reports. 24 (10): 385–394. doi:10.1007/s11906-022-01205-5. PMC 9509303. PMID 35704141.
  66. ^ Calvi, A; Fischetti, I; Verzicco, I; Belvederi Murri, M; Zanetidou, S; Volpi, R; Coghi, P; Tedeschi, S; Amore, M; Cabassi, A (2021). "Antidepressant Drugs Effects on Blood Pressure". Frontiers in Cardiovascular Medicine. 8: 704281. doi:10.3389/fcvm.2021.704281. PMC 8370473. PMID 34414219.
  67. ^ Salerno, SM; Jackson, JL; Berbano, EP (8–22 August 2005). "Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis". Archives of Internal Medicine. 165 (15): 1686–94. doi:10.1001/archinte.165.15.1686. PMID 16087815.
  68. ^ Varon J, Marik PE (2008). "Perioperative hypertension management". Vasc Health Risk Manag. 4 (3): 615–27. doi:10.2147/VHRM.S2471. PMC 2515421. PMID 18827911.
  69. ^ Williams B, et al. (2006). "Secondary Hypertension". Hypertension Etiology & Classification - Secondary Hypertension. Armenian Medical Network. Retrieved 2 December 2007.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Secondary_hypertension&oldid=1245865974"